Metformin promotes cGAS/STING signaling pathway activation by blocking AKT phosphorylation in gastric cancer

被引:11
作者
Shen, Qian [1 ]
Yang, Lei [1 ]
Li, Chengguo [1 ]
Wang, Tao [1 ]
Lv, Jianbo [1 ]
Liu, Weizhen [1 ]
Lin, Yao [1 ]
Yin, Yuping [1 ]
Tao, Kaixiong [1 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, Wuhan, Peoples R China
基金
中国国家自然科学基金;
关键词
Gastric cancer; Metformin; cGAS/STING; AKT; SOX2; AMPK;
D O I
10.1016/j.heliyon.2023.e18954
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The cGAS/STING signaling pathway plays a pivotal role in regulating innate immunity. Emerging novel drugs aim to regulate the anti-tumor immune response by activating innate immunity. The anti-diabetic drug metformin has been reported to exhibit anti-cancer effect against various types of cancer. However, the role of metformin in regulating the cGAS/STING signaling pathway in gastric cancer remains unknown. In our study, we first used bioinformatic analysis to detect that metformin is closely related to tumor immunity in multiple tumors. Next, we validated the function of metformin in activating the cGAS/STING signaling pathway in gastric cancer cell lines. In addition, KEGG pathway enrichment analysis showed that metformin is negatively correlated with the PI3K/AKT signaling pathway in gastric cancer. We further verified that metformin activates the cGAS/STING signaling pathway by blocking AKT phosphorylation. Moreover, we found that metformin regulates the AKT signaling pathway by mediating the transcription factor SOX2. Thus, our study indicates that metformin activates the cGAS/STING signaling pathway by suppressing SOX2/AKT and has promising potential in gastric cancer immunotherapy.
引用
收藏
页数:11
相关论文
共 36 条
[1]   Gastric Cancer, Version 2.2022 [J].
Ajani, Jaffer A. ;
D'Amico, Thomas A. ;
Bentrem, David J. ;
Chao, Joseph ;
Cooke, David ;
Corvera, Carlos ;
Das, Prajnan ;
Enzinger, Peter C. ;
Enzler, Thomas ;
Fanta, Paul ;
Farjah, Farhood ;
Gerdes, Hans ;
Gibson, Michael K. ;
Hochwald, Steven ;
Hofstetter, Wayne L. ;
Ilson, David H. ;
Keswani, Rajesh N. ;
Kim, Sunnie ;
Kleinberg, Lawrence R. ;
Klempner, Samuel J. ;
Lacy, Jill ;
Ly, Quan P. ;
Matkowskyj, Kristina A. ;
McNamara, Michael ;
Mulcahy, Mary F. ;
Outlaw, Darryl ;
Park, Haeseong ;
Perry, Kyle A. ;
Pimiento, Jose ;
Poultsides, George A. ;
Reznik, Scott ;
Roses, Robert E. ;
Strong, Vivian E. ;
Su, Stacey ;
Wang, Hanlin L. ;
Wiesner, Georgia ;
Willett, Christopher G. ;
Yakoub, Danny ;
Yoon, Harry ;
McMillian, Nicole ;
Pluchino, Lenora A. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (02) :167-192
[2]   Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].
Brahmer, Julie R. ;
Tykodi, Scott S. ;
Chow, Laura Q. M. ;
Hwu, Wen-Jen ;
Topalian, Suzanne L. ;
Hwu, Patrick ;
Drake, Charles G. ;
Camacho, Luis H. ;
Kauh, John ;
Odunsi, Kunle ;
Pitot, Henry C. ;
Hamid, Omid ;
Bhatia, Shailender ;
Martins, Renato ;
Eaton, Keith ;
Chen, Shuming ;
Salay, Theresa M. ;
Alaparthy, Suresh ;
Grosso, Joseph F. ;
Korman, Alan J. ;
Parker, Susan M. ;
Agrawal, Shruti ;
Goldberg, Stacie M. ;
Pardoll, Drew M. ;
Gupta, Ashok ;
Wigginton, Jon M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465
[3]   Metformin exerts anti-AR-negative prostate cancer activity via AMPK/autophagy signaling pathway [J].
Chen, Chunyang ;
Wang, He ;
Geng, Xinyu ;
Zhang, Dongze ;
Zhu, Zhengyu ;
Zhang, Guangbo ;
Hou, Jianquan .
CANCER CELL INTERNATIONAL, 2021, 21 (01)
[4]   A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data [J].
Chen, Li-Tzong ;
Satoh, Taroh ;
Ryu, Min-Hee ;
Chao, Yee ;
Kato, Ken ;
Chung, Hyun Cheol ;
Chen, Jen-Shi ;
Muro, Kei ;
Kang, Won Ki ;
Yeh, Kun-Huei ;
Yoshikawa, Takaki ;
Oh, Sang Cheul ;
Bai, Li-Yuan ;
Tamura, Takao ;
Lee, Keun-Wook ;
Hamamoto, Yasuo ;
Kim, Jong Gwang ;
Chin, Keisho ;
Oh, Do-Youn ;
Minashi, Keiko ;
Cho, Jae Yong ;
Tsuda, Masahiro ;
Sameshima, Hiroki ;
Kang, Yoon-Koo ;
Boku, Narikazu .
GASTRIC CANCER, 2020, 23 (03) :510-519
[5]   Metformin induces apoptosis and inhibits migration by activating the AMPK/p53 axis and suppressing PI3K/AKT signaling in human cervical cancer cells [J].
Chen, Ya-Hui ;
Yang, Shun-Fa ;
Yang, Chueh-Ko ;
Tsai, Horng-Der ;
Chen, Tze-Ho ;
Chou, Ming-Chih ;
Hsiao, Yi-Hsuan .
MOLECULAR MEDICINE REPORTS, 2021, 23 (01) :1-11
[6]   Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells [J].
Dowling, Ryan J. O. ;
Zakikhani, Mahvash ;
Fantus, I. George ;
Pollak, Michael ;
Sonenberg, Nahum .
CANCER RESEARCH, 2007, 67 (22) :10804-10812
[7]   Immune-mediated antitumor effect by type 2 diabetes drug, metformin [J].
Eikawa, Shingo ;
Nishida, Mikako ;
Mizukami, Shusaku ;
Yamazaki, Chihiro ;
Nakayama, Eiichi ;
Udono, Heiichiro .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (06) :1809-1814
[8]   Molecular mechanisms underlining the role of metformin as a therapeutic agent in lung cancer [J].
Fatehi Hassanabad, Ali ;
MacQueen, Kelsey T. .
CELLULAR ONCOLOGY, 2021, 44 (01) :1-18
[9]   Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer [J].
Gulati, Shuchi ;
Desai, Janki ;
Palackdharry, Sarah M. ;
Morris, John C. ;
Zhu, Zheng ;
Jandarov, Roman ;
Riaz, Muhammad K. ;
Takiar, Vinita ;
Mierzwa, Michelle ;
Gutkind, J. Silvio ;
Molinolo, Alfredo ;
Desai, Pankaj B. ;
Sadraei, Nooshin Hashemi ;
Wise-Draper, Trisha M. .
CANCER, 2020, 126 (02) :354-362
[10]   AMPK: a nutrient and energy sensor that maintains energy homeostasis [J].
Hardie, D. Grahame ;
Ross, Fiona A. ;
Hawley, Simon A. .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2012, 13 (04) :251-262